oxonic acid has been researched along with Neoplasm Metastasis in 169 studies
Oxonic Acid: Antagonist of urate oxidase.
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC)." | 9.41 | Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III ( Baba, H; Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kotake, M; Morita, S; Nakamura, M; Ohori, H; Sakashita, A; Sato, A; Shimada, K; Takahashi, M; Takahashi, S; Takashima, A; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2021) |
| "The aim of this single-arm phase II clinical trial was to evaluate whether the alternate-day administration of S-1 plus irinotecan would reduce the incidence of severe diarrhea in comparison to consecutive-day S-1 administration (standard IRIS regimen) in second-line treatment for patients with metastatic colorectal cancer." | 9.27 | A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. ( Honda, M; Kim, HM; Kondo, K; Kosugi, C; Matsuda, C; Mishima, H; Oba, K; Sakamoto, J; Takahashi, T; Takemoto, H; Tanaka, C; Tokunaga, Y, 2018) |
| "Irinotecan plus S-1 (IRIS) is the only oral fluoropyrimidine-based regimen reported to be non-inferior to FOLFIRI and widely used in clinical practice for metastatic colorectal cancer (mCRC) patients." | 9.22 | Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer. ( Goda, F; Goji, T; Kawamoto, S; Kimura, M; Kimura, T; Kitamura, S; Miyamoto, H; Muguruma, N; Negoro, Y; Niitsu, Y; Okahisa, T; Okamoto, K; Sakamoto, K; Shimoyama, R; Takaoka, T; Takayama, T; Tsuji, A; Yano, H; Yoshizaki, K, 2016) |
| "S-1, a novel oral prodrug of 5-fluorouracil (5-FU), and irinotecan with or without bevacizumab is known to be effective in metastatic colorectal cancer (mCRC)." | 9.20 | S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. ( Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H, 2015) |
| "A phase II study was conducted to evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer (BTC)." | 9.20 | Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. ( Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY, 2015) |
| "We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer." | 9.19 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2014) |
| "Forty-two chemo-naive patients with metastatic colorectal cancer (mCRC) were planned to be enrolled and be treated with irinotecan 150 mg m(-2) followed by oxaliplatin 85 mg m(-2) on day 1 and S-1 80 mg m(-2) per day from day 1 to 14 every 3 weeks." | 9.17 | S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. ( Baek, JY; Jung, KH; K Shim, E; Kim, SY; Kong, SY; S Hong, Y; Shin, A, 2013) |
| "The current study aimed to assess the long-term efficacy of combination therapy with oral S-1, a fluoropyrimidine prodrug, plus irinotecan in previously untreated patients with metastatic colorectal cancer." | 9.16 | Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer. ( Goto, A; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Shimada, Y; Yamada, Y, 2012) |
| "Fluorouracil (5-FU) plus irinotecan combined with bevacizumab has significant activity in metastatic colorectal cancer (mCRC), but S-1 has become a substitute for continuous infusion of 5-FU and has a very low incidence of hand-foot syndrome." | 9.16 | Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. ( Goto, A; Hamaguchi, T; Ichikawa, Y; Kato, K; Matsumoto, H; Shimada, Y; Yamada, Y; Yamaguchi, T, 2012) |
| "To investigate the combination of S-1 and irinotecan (CPT-11) as an alternative to infusional 5-fluorouracil/leucovorin plus CPT-11, we performed a phase I trial to determine the maximum tolerated dose, recommended dose (RD), and dose-limiting toxicities (DLTs) in patients with metastatic or recurrent colorectal cancer." | 9.15 | A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer. ( Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Ryu, MH, 2011) |
| "We aimed to evaluate the efficacy and safety of gemcitabine/S-1 combination chemotherapy for the treatment of patients with advanced biliary tract cancer." | 9.15 | A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. ( Asada, M; Chiba, T; Fukushima, M; Hamada, A; Hatano, E; Ikai, I; Inoue, N; Kanai, M; Matsumoto, S; Mori, Y; Niimi, M; Nishimura, T; Nitta, T; Osaki, Y; Suzuki, C; Tada, S; Taura, K; Tsumura, T; Uemoto, S; Yanagihara, K; Yasuchika, K; Yazumi, S; Yoshimura, K, 2011) |
| "Three-drug combination of fluoropyrimidine, irinotecan and oxaliplatin has shown survival benefits in patients with metastatic colorectal cancer (mCRC)." | 9.14 | A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer. ( Choi, HS; Hong, CW; Hong, YS; Jeong, SY; Jung, KH; Kim, BC; Kim, DY; Kim, SY; Park, JW; Sohn, DK, 2009) |
| "Background Combination therapy of gemcitabine with cisplatin (GC) is a standard first-line therapy for unresectable or recurrent biliary tract cancer (BTC)." | 8.02 | Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer. ( Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2021) |
| "Tegafur-gimeracil-oteracil potassium (TS-1)is a drug that is used mainly as a third-line treatment or beyond for metastatic breast cancer(MBC)." | 7.80 | Effectiveness and safety of tegafur-gimeracil-oteracil potassium (TS-1) for metastatic breast cancer: a single-center retrospective study. ( Ishizuna, K; Kawashima, M; Kojima, M; Ninomiya, J; Nozaki, M; Ogawa, T; Tsuji, E; Ueda, Y; Yamagishi, H, 2014) |
| "Chemotherapy with irinotecan (CPT-11) or oxaliplatin (l-OHP) in combination with infusional 5-fluorouracil (5-FU) and their cross-over as second-line therapies are standard treatments for metastatic colorectal cancer (MCRC)." | 7.75 | Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. ( Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2009) |
| " Based on this enzymatic characteristic of pulmonary metastases of breast cancer in regard to 5-FU metabolism, we investigated the antitumor activity of two types of oral 5-FU prodrugs, with and without paclitaxel, on both orthotopically implanted breast tumors and metastatic lung tumors in mice." | 7.72 | Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. ( Fujioka, A; Fukushima, M; Kitazato, K; Nagayama, S; Nakagawa, F; Nukatsuka, M; Oshimo, H; Sugimoto, Y; Uchida, J, 2004) |
| "Irinotecan (125 mg/m(2)) was administered as a 24-hour infusion on days 1 and 15, S-1 (80 mg/m(2)) was administered orally on days 1-14, and bevacizumab (5." | 6.80 | A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer. ( Kamijo, A; Okada, K; Sadahiro, S; Saito, G; Suzuki, T; Tanaka, A, 2015) |
| "However, its efficacy in treating advanced head and neck neoplasms has not been reported." | 5.51 | Apatinib and S-1 combination therapy for the treatment of advanced head and neck neoplasms: Three case reports. ( Han, X; Huang, G; Li, W; Meng, M; Ni, Y; Wang, J; Wei, Z; Yang, X; Ye, X, 2019) |
| "The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC)." | 5.41 | Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III ( Baba, H; Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kotake, M; Morita, S; Nakamura, M; Ohori, H; Sakashita, A; Sato, A; Shimada, K; Takahashi, M; Takahashi, S; Takashima, A; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2021) |
| "Under the diagnosis of multiple lung metastases, the patient was hospitalized and received intensive chemotherapy with docetaxel 40 mg/week (day 1), 5-fluorouracil 500 mg/day (days 1-5), cisplatin 10 mg/day (days 1-5)." | 5.33 | A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy. ( Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T, 2006) |
| "The aim of this single-arm phase II clinical trial was to evaluate whether the alternate-day administration of S-1 plus irinotecan would reduce the incidence of severe diarrhea in comparison to consecutive-day S-1 administration (standard IRIS regimen) in second-line treatment for patients with metastatic colorectal cancer." | 5.27 | A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. ( Honda, M; Kim, HM; Kondo, K; Kosugi, C; Matsuda, C; Mishima, H; Oba, K; Sakamoto, J; Takahashi, T; Takemoto, H; Tanaka, C; Tokunaga, Y, 2018) |
| "Irinotecan plus S-1 (IRIS) is the only oral fluoropyrimidine-based regimen reported to be non-inferior to FOLFIRI and widely used in clinical practice for metastatic colorectal cancer (mCRC) patients." | 5.22 | Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer. ( Goda, F; Goji, T; Kawamoto, S; Kimura, M; Kimura, T; Kitamura, S; Miyamoto, H; Muguruma, N; Negoro, Y; Niitsu, Y; Okahisa, T; Okamoto, K; Sakamoto, K; Shimoyama, R; Takaoka, T; Takayama, T; Tsuji, A; Yano, H; Yoshizaki, K, 2016) |
| "S-1, a novel oral prodrug of 5-fluorouracil (5-FU), and irinotecan with or without bevacizumab is known to be effective in metastatic colorectal cancer (mCRC)." | 5.20 | S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. ( Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H, 2015) |
| "A phase II study was conducted to evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer (BTC)." | 5.20 | Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. ( Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY, 2015) |
| "We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer." | 5.19 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2014) |
| "We conducted a phase I study of S-1 combined with irinotecan and oxaliplatin (TIROX) to determine the maximum-tolerated dose (MTD) and recommended dose (RD) and to assess its safety, pharmacokinetics, pharmacogenetics, and preliminary efficacy in patients with metastatic colorectal cancer (MCRC) or metastatic gastric cancer (MGC)." | 5.17 | Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. ( Hong, YS; Jung, KH; Kim, SY; Kong, SY; Lim, HS; Park, SR; Park, YI; Seong, MW, 2013) |
| "Forty-two chemo-naive patients with metastatic colorectal cancer (mCRC) were planned to be enrolled and be treated with irinotecan 150 mg m(-2) followed by oxaliplatin 85 mg m(-2) on day 1 and S-1 80 mg m(-2) per day from day 1 to 14 every 3 weeks." | 5.17 | S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. ( Baek, JY; Jung, KH; K Shim, E; Kim, SY; Kong, SY; S Hong, Y; Shin, A, 2013) |
| "Fluorouracil (5-FU) plus irinotecan combined with bevacizumab has significant activity in metastatic colorectal cancer (mCRC), but S-1 has become a substitute for continuous infusion of 5-FU and has a very low incidence of hand-foot syndrome." | 5.16 | Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. ( Goto, A; Hamaguchi, T; Ichikawa, Y; Kato, K; Matsumoto, H; Shimada, Y; Yamada, Y; Yamaguchi, T, 2012) |
| "The current study aimed to assess the long-term efficacy of combination therapy with oral S-1, a fluoropyrimidine prodrug, plus irinotecan in previously untreated patients with metastatic colorectal cancer." | 5.16 | Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer. ( Goto, A; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Shimada, Y; Yamada, Y, 2012) |
| "We aimed to evaluate the efficacy and safety of gemcitabine/S-1 combination chemotherapy for the treatment of patients with advanced biliary tract cancer." | 5.15 | A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. ( Asada, M; Chiba, T; Fukushima, M; Hamada, A; Hatano, E; Ikai, I; Inoue, N; Kanai, M; Matsumoto, S; Mori, Y; Niimi, M; Nishimura, T; Nitta, T; Osaki, Y; Suzuki, C; Tada, S; Taura, K; Tsumura, T; Uemoto, S; Yanagihara, K; Yasuchika, K; Yazumi, S; Yoshimura, K, 2011) |
| "To investigate the combination of S-1 and irinotecan (CPT-11) as an alternative to infusional 5-fluorouracil/leucovorin plus CPT-11, we performed a phase I trial to determine the maximum tolerated dose, recommended dose (RD), and dose-limiting toxicities (DLTs) in patients with metastatic or recurrent colorectal cancer." | 5.15 | A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer. ( Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Ryu, MH, 2011) |
| "A combination of fluorouracil and leucovorin (5-FU/LV) with oxaliplatin (FOLFOX) is an established first-line therapy for metastatic colorectal cancer (mCRC)." | 5.15 | Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study. ( Fujiwara, M; Iwata, N; Kodera, Y; Koike, M; Nakao, A; Nakayama, G; Ohashi, N; Okuda, N; Tanaka, C; Watanabe, T; Yokoyama, H, 2011) |
| "Three-drug combination of fluoropyrimidine, irinotecan and oxaliplatin has shown survival benefits in patients with metastatic colorectal cancer (mCRC)." | 5.14 | A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer. ( Choi, HS; Hong, CW; Hong, YS; Jeong, SY; Jung, KH; Kim, BC; Kim, DY; Kim, SY; Park, JW; Sohn, DK, 2009) |
| "Eligibility criteria were histologically proven pancreatic adenocarcinoma with confirmation of progressive disease while receiving gemcitabine-based first-line chemotherapy, 20-74 years of age, Karnofsky performance status of 80-100 points, with measurable metastatic lesions, adequate hematological, renal and liver functions, and written informed consent." | 5.14 | A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. ( Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Najima, M; Nakachi, K; Ogura, T; Okusaka, T; Suzuki, E; Ueno, H, 2009) |
| "Background Combination therapy of gemcitabine with cisplatin (GC) is a standard first-line therapy for unresectable or recurrent biliary tract cancer (BTC)." | 4.02 | Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer. ( Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2021) |
| " SELECT BC compared S-1 and taxane as first-line treatment for metastatic breast cancer." | 3.91 | Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study. ( Chishima, T; Doihara, H; Hozumi, Y; Ishikawa, T; Miyoshi, Y; Morimoto, T; Mukai, H; Narui, K; Nishimura, R; Ohashi, Y; Ohno, S; Suto, A; Tamura, M; Uemura, Y; Yoshino, H; Zaha, H, 2019) |
| "Tegafur-gimeracil-oteracil potassium (TS-1)is a drug that is used mainly as a third-line treatment or beyond for metastatic breast cancer(MBC)." | 3.80 | Effectiveness and safety of tegafur-gimeracil-oteracil potassium (TS-1) for metastatic breast cancer: a single-center retrospective study. ( Ishizuna, K; Kawashima, M; Kojima, M; Ninomiya, J; Nozaki, M; Ogawa, T; Tsuji, E; Ueda, Y; Yamagishi, H, 2014) |
| "Chemotherapy with irinotecan (CPT-11) or oxaliplatin (l-OHP) in combination with infusional 5-fluorouracil (5-FU) and their cross-over as second-line therapies are standard treatments for metastatic colorectal cancer (MCRC)." | 3.75 | Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. ( Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2009) |
| " Based on this enzymatic characteristic of pulmonary metastases of breast cancer in regard to 5-FU metabolism, we investigated the antitumor activity of two types of oral 5-FU prodrugs, with and without paclitaxel, on both orthotopically implanted breast tumors and metastatic lung tumors in mice." | 3.72 | Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. ( Fujioka, A; Fukushima, M; Kitazato, K; Nagayama, S; Nakagawa, F; Nukatsuka, M; Oshimo, H; Sugimoto, Y; Uchida, J, 2004) |
| " Recently, superiority of IP administration of paclitaxel (PTX) combined with S-1 and intravenous PTX over conventional systemic chemotherapy was suggested in a phase III study, although the difference in overall survival did not reach statistical significance in the primary analysis." | 2.94 | Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis. ( Ishigami, H; Kanda, M; Kitayama, J; Kobayashi, D; Kodera, Y; Tanaka, C; Yamaguchi, H, 2020) |
| "Patients with HER2-positive gastric cancer without measurable lesions received cisplatin plus trastuzumab intravenously on day 1 and oral S-1 on days 1-14 of a 21-day cycle." | 2.90 | Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202. ( Endo, S; Gamoh, M; Kawabata, R; Kawada, J; Kimura, Y; Kobayashi, K; Kurokawa, Y; Masuzawa, T; Matsuyama, J; Sakai, D; Satoh, T; Shimokawa, T; Takeno, A; Taniguchi, H; Yamamoto, K, 2019) |
| "The aim of this study was to investigate the impact of adverse events (AEs) on health utility and health-related quality of life (HRQOL) in patients with metastatic breast cancer undergoing first-line chemotherapy." | 2.87 | Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study. ( Fukuda, T; Hagiwara, Y; Kawahara, T; Mukai, H; Ohashi, Y; Shimozuma, K; Shiroiwa, T; Taira, N; Uemura, Y; Watanabe, T, 2018) |
| " This study evaluated the efficacy of intensity modulated radiotherapy in combination with gemcitabine and S-1 as neoadjuvant chemoradiotherapy (NACRT) for borderline-resectable pancreatic cancer with arterial involvement (BR-A)." | 2.84 | A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement. ( Hijikata, Y; Hosokawa, Y; Kasuya, K; Katsumata, K; Nagakawa, Y; Nakajima, T; Nakayama, H; Sahara, Y; Takishita, C; Tokuuye, K; Tsuchida, A, 2017) |
| "Paclitaxel was administered intravenously at a dose of 120 mg/m(2) on day 1 and oral S-1 was given twice daily (BSA < 1." | 2.80 | A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer. ( Chen, L; Fang, W; Jiang, H; Mao, C; Mou, H; Qian, J; Teng, L; Wang, Y; Xu, N; Zhang, X; Zhao, P; Zheng, Y, 2015) |
| "The use of trastuzumab, a monoclonal antibody targeting the HER2 protein, in combination with 5-fluorouracil/platinum-based chemotherapy improves survival in patients with HER2-positive advanced gastric cancer." | 2.80 | Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. ( Choo, SP; Chua, C; Iwasa, S; Lim, HY; Ng, M; Ong, WS; Rha, SY; Tai, DW; Tan, IB; Tham, CK; Yamada, Y; Yong, WP, 2015) |
| "Irinotecan (125 mg/m(2)) was administered as a 24-hour infusion on days 1 and 15, S-1 (80 mg/m(2)) was administered orally on days 1-14, and bevacizumab (5." | 2.80 | A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer. ( Kamijo, A; Okada, K; Sadahiro, S; Saito, G; Suzuki, T; Tanaka, A, 2015) |
| "Patients with advanced pancreatic cancer were eligible for enrollment in this trial." | 2.79 | Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. ( Chijiiwa, K; Egawa, S; Hayashi, K; Hirono, S; Kanbe, T; Kato, J; Kawai, M; Kwon, AH; Miyazawa, M; Mukouyama, T; Ohuchida, J; Okada, K; Satoi, S; Shirasaka, T; Tani, M; Tsunoda, H; Ueda, K; Yamaguchi, T; Yamaue, H; Yanagimoto, H, 2014) |
| "As first-line treatment for advanced gastric cancer, docetaxel plus S-1 significantly improves median overall and progression-free survival as compared with S-1 alone." | 2.79 | Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). ( Cho, JY; Chung, HC; Fujii, M; Hara, T; Hosaka, H; Imamura, H; Inokuchi, M; Kim, HK; Kim, YH; Koizumi, W; Lee, KH; Nakajima, T; Ogura, M; Okuno, T; Satoh, T; Takagane, A; Takeuchi, M; Tanabe, K; Tsuji, A; Yoshida, K, 2014) |
| "Peritoneal metastasis is treated more effectively by this regimen than other forms of metastases." | 2.78 | Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor. ( Chen, Y; Cui, Y; Feng, Y; Li, Q; Liu, T; Wang, Y; Yu, Y, 2013) |
| " The dosage of S-1 was based on the body surface area (BSA) as follows: 40 mg bid (total 80 mg/day) for a BSA of <1." | 2.78 | Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. ( Choi, DR; Han, B; Jang, G; Jeon, JY; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, IG; Kim, JH; Kwon, JH; Park, CK; Song, H; Zang, DY, 2013) |
| "Paclitaxel and cisplatin were infused on days 1 and 15." | 2.77 | Phase I study of combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 in patients with unresectable gastric cancer (KOGC-02). ( Fukuda, K; Funakoshi, S; Kawakubo, H; Kitagawa, Y; Saikawa, Y; Takahashi, T; Takaishi, H; Takeuchi, H, 2012) |
| " We conducted a phase I study to evaluate the safety and pharmacokinetic of TSU-68 when used with S-1 and oxaliplatin (SOX) in metastatic colorectal cancer (mCRC) patients." | 2.77 | A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. ( Ahn, JB; Chung, HC; Jeung, HC; Jung, M; Kim, HR; Rha, SY; Roh, JK; Shin, SJ, 2012) |
| "As there are no reports of S-1 in combination with trastuzumab in clinical settings, we evaluated the safety and efficacy of S-1 in combination with trastuzumab for human epidermal-growth factor receptor (HER2)-positive metastatic breast cancer (MBC) and determined the recommended dose (RD)." | 2.76 | Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. ( Ito, T; Kamigaki, S; Morita, S; Nakayama, T; Noguchi, S; Sakamoto, J; Taguchi, T; Takashima, T; Yoshidome, K, 2011) |
| "Standard chemotherapy for advanced gastric cancer was changed to S-1/CDDP by SPIRITS phase III trial which was presented just after this trial was initiated, which would be a major cause of slow accrual." | 2.76 | [Randomized phase II trial to compare S-1 and S-1/PSK for advanced or recurrent gastric cancer-lessons from the results]. ( Aoyama, T; Hasegawa, S; Kanemoto, A; Saze, Z; Tahara, H; Terashima, M; Tsuburaya, A; Yoshikawa, T, 2011) |
| "To evaluate the efficacy, safety and pharmacokinetic profiles of S-1, which composed of tegafur (FT, a prodrug of 5-FU), 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), in Taiwanese advanced gastric cancer (AGC) patients." | 2.76 | A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. ( Chao, TY; Chao, Y; Chen, JS; Chen, LT; Chen, PM; Cheng, AL; Chiou, TJ; Hsieh, RK; Whang-Peng, J; Yeh, KH, 2011) |
| " We investigated the activity and toxicity of S-1 in combination with cisplatin in patients with unresectable non-small cell lung cancer (NSCLC)." | 2.76 | An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer. ( Baggstrom, M; Graham, C; Herbst, R; Jones, D; Saito, K; Sandler, A; Zergebel, C, 2011) |
| "Gemcitabine was administered at a dose of 1000 mg/m(2) over 30 min on days 1 and 8, and oral S-1 at a dose of 40 mg/m(2) twice daily from days 1 to 14, repeated every 3 weeks." | 2.76 | Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. ( Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O, 2011) |
| "The response rate of S-1 for colorectal cancer is high, ranging from 35% to 40%." | 2.75 | Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. ( Boku, N; Furuhata, T; Hyodo, I; Kato, T; Koizumi, W; Miyashita, K; Miyata, Y; Nishina, T; Okada, Y; Sawaki, A; Toh, Y; Yamaguchi, K, 2010) |
| "Patients with hormone-resistant breast cancer are assigned to either TS-1 (40-60 mg twice daily for 28 consecutive days, followed by a 14-day rest period) or standard chemotherapy (docetaxel 60-75 mg/m(2) at 3- or 4-week intervals, paclitaxel 175 mg/m(2) at 3- or 4-week intervals or paclitaxel 80-100 mg/m(2) weekly, followed by a 1-week rest period)." | 2.75 | Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC). ( Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T, 2010) |
| "Patients with metastatic or recurrent gastric cancer, no prior chemotherapy, measurable disease, ECOG performance status less than 3 and adequate organ functions were eligible for the study." | 2.74 | Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer. ( Ariyama, H; Baba, E; Esaki, T; Fujishima, H; Harada, M; Kato, K; Kusaba, H; Mitsugi, K; Nakano, S; Shibata, Y; Tanaka, R, 2009) |
| "S-1 showed clinical activity in colorectal cancer, and the preclinical data of S-1 with oxaliplatin showed synergistic activity in an animal model." | 2.74 | A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer. ( Kang, EM; Kang, WK; Kim, HS; Lee, HY; Lee, J; Lee, Y; Lim, HY; Park, JO; Park, MJ; Park, SH; Park, YS; Uhm, JE, 2009) |
| "The purpose of this study was to determine the optimal dose of oxaliplatin, when combined with a fixed dose of S-1 (40 mg/m twice daily on days 1-14) on a 3-week schedule, for patients with advanced and/or metastatic colorectal cancer." | 2.73 | Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer. ( Cao, J; Li, J; Liu, Y; Lu, F; Yin, J; Zhu, X; Zuo, Y, 2008) |
| "Although fatigue was the most frequently encountered toxicity safety profiles were generally predictable and manageable." | 2.73 | Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. ( Cho, EK; Chung, M; Hong, J; Kim, YS; Lee, JH; Lee, WK; Nam, E; Park, J; Park, SH; Shin, DB, 2008) |
| "Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine." | 2.73 | Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. ( Arai, K; Fujii, M; Furukawa, H; Higashino, M; Imamura, H; Kinoshita, T; Kurita, A; Nakajima, T; Nashimoto, A; Ohashi, Y; Sakuramoto, S; Sasako, M; Yamaguchi, T; Yamamura, Y, 2007) |
| "We designed a phase I/II trial of S-1 combined with weekly docetaxel to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate the efficacy and toxicity in metastatic gastric carcinoma (MGC)." | 2.73 | Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma. ( Bae, JM; Choi, IJ; Kim, CG; Kim, HK; Kim, NK; Kim, YW; Lee, JH; Lee, JS; Park, SR; Ryu, KW, 2008) |
| "We conducted a phase II trial of gemcitabine with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic pancreatic cancer (MPC) patients." | 2.72 | Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. ( Ishihara, T; Kato, H; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T, 2006) |
| "In total 47 patients with colorectal cancer were included." | 2.71 | EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. ( de Boer, RF; Duffaud, F; Fumoleau, P; Reinke, F; Roth, AD; Schellens, JH; Schöffski, P; Van den Brande, J; Vermorken, JB; Wanders, J; Weigang-Köhler, K, 2003) |
| "Patients with measurable metastasis foci (n=111) were enrolled, and 108 patients were regarded as eligible." | 2.71 | A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. ( Aoyama, H; Horikoshi, N; Kimura, M; Miura, S; Morimoto, K; Noguchi, S; Ota, J; Saek, T; Sano, M; Shimizu, S; Taguchi, T; Takashima, S, 2004) |
| "Paclitaxel was scheduled to be given intravenously on days 1 and 8 at a dose of 50, 60, 70 or 80 mg/m(2), depending on the DLTs." | 2.71 | Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. ( Fujitani, K; Furukawa, H; Gotoh, M; Hirao, M; Narahara, H; Satomi, E; Taguchi, T; Takiuchi, H; Tsujinaka, T, 2005) |
| " Odds ratio and hazard ratio of available outcomes including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were pooled for analysis." | 2.61 | Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis. ( Chen, J; Wang, J; Xu, T, 2019) |
| "This review aims to provide an evidence-based update of clinical trials that have investigated the clinical efficacy, adverse-event profile, dosage and administration of S-1, given alone or in combination with conventional chemotherapeutics and new target-oriented drugs, in the management of colorectal cancer (CRC)." | 2.50 | Efficacy of S-1 in colorectal cancer. ( Baba, H; Miyamoto, Y; Sakamoto, Y; Yoshida, N, 2014) |
| "The prognosis for hepatocellular carcinoma with extrahepatic metastasis or vascular invasion is very poor." | 2.47 | [A successful case of systemic chemotherapy followed by liver resection for advanced hepatocellular carcinoma with highly vascular invasion and multiple pulmonary metastases]. ( Kakisaka, T; Kamachi, H; Kamiyama, T; Matsushita, M; Mizukami, T; Nakanishi, K; Tahara, M; Taniguchi, M; Todo, S; Yokoo, H, 2011) |
| "DC-CIK combined with S-1 plus cisplatin provided a favorable PFS and OS in patients with AGC and the combination therapy was safe with tolerable toxicities." | 1.51 | Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. ( Hobeika, A; Lyerly, HK; Morse, MA; Qiao, G; Ren, J; Song, J; Song, Y; Wang, S; Wang, X; Xia, X; Yi, X; Zhao, L; Zhou, L; Zhou, X, 2019) |
| "However, its efficacy in treating advanced head and neck neoplasms has not been reported." | 1.51 | Apatinib and S-1 combination therapy for the treatment of advanced head and neck neoplasms: Three case reports. ( Han, X; Huang, G; Li, W; Meng, M; Ni, Y; Wang, J; Wei, Z; Yang, X; Ye, X, 2019) |
| "Gemcitabine plus S-1 is a viable treatment alternative to gemcitabine, which is one of the standard treatments in patients with LAPC." | 1.46 | Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. ( Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T, 2017) |
| "The mean recurrence-free survival was 13." | 1.43 | [Adjuvant Systemic Chemotherapy with S-1/Oxaliplatin or mFOLFOX6 after Curative Resection of Distant Metastases in Patients with Colorectal Cancer]. ( Amada, E; Baba, S; Kameyama, N; Mitsuhashi, H; Miyata, R; Tomita, M, 2016) |
| "To observe the short-term efficacy and safety of S-1 combined with cisplatin (DDP) chemotherapy for advanced gastric cancer (AGC)." | 1.43 | S-1 combined with cisplatin chemotherapy for advanced gastric cancer. ( Lijun, X; Weidong, C, 2016) |
| "Chemotherapy for unresectable pancreatic cancer should not only prolong survival but maintain quality of life, considering its limited life expectancy." | 1.42 | Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study. ( Amano, H; Ikeda, Y; Ito, H; Kainuma, M; Miura, F; Sano, K; Shibuya, M; Takada, T; Toyota, N; Wada, K, 2015) |
| " S-1 was shown to be effective and safe in Japanese metastatic breast cancer patients treated with previous chemotherapy, including anthracyclines." | 1.42 | Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study. ( Hirokawa, E; Kanbayashi, C; Nakamiya, N; Osaki, A; Saeki, T; Sano, H; Sato, N; Sekine, H; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S, 2015) |
| " Most adverse events were mild." | 1.40 | Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis. ( Chen, ZB; Cheng, H; Lin, Z; Liu, YM; Ou, XQ; Peng, PJ; Tang, YN; Wang, SY; Wu, X; Zeng, LJ; Zhang, HY, 2014) |
| " Adverse events were observed in 27 patients(77%), and adverse events of Grade >3 were observed in 7 patients(20%)." | 1.40 | [Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer - an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)]. ( Hayashi, K; Iwase, H; Kawano, I; Kuramoto, M; Nishimura, R; Tanigawa, T; Yamamoto, Y; Yamamoto-Ibusuki, M, 2014) |
| "GEM improved prognosis of patients with gallbladder cancer after R1/R2 resections." | 1.40 | Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer. ( Abe, T; Ensako, T; Hino, K; Nakamura, M; Nakashima, H; Yoshida, K, 2014) |
| "Fifty-five cases of advanced gastric cancer received pre-operative treatment with S-1 and CDDP." | 1.39 | [Preoperative chemotherapy for advanced gastric cancer]. ( Amagasa, H; Ami, K; Ando, M; Arai, K; Fujiya, K; Fukuda, A; Ganno, H; Kamikozuru, H; Nagahama, T; Seki, R; Takasaki, J; Tei, S, 2013) |
| "In resectable advanced laryngeal cancer, S-1 adjuvant chemotherapy is an effective and feasible treatment option to control distant metastases following reduced RADPLAT." | 1.38 | Adjuvant chemotherapy with an oral fluoropyrimidine, S-1, following reduced RADPLAT in advanced laryngeal cancer. ( Endo, K; Kondo, S; Murono, S; Wakisaka, N; Yoshizaki, T, 2012) |
| "Since no obvious metastasis was recognized by abdominal computed tomography(CT), he underwent distal gastrectomy with D1+ lymphadenectomy." | 1.38 | [A case of early gastric cancer with cervical lymph nodes recurrence 5 years after a curative resection]. ( Amano, R; Hirakawa, K; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Noda, E; Ohira, M; Sakurai, K; Sawada, T; Tanaka, H, 2012) |
| "She had multiple metastases of lungs, lymph nodes, bilateral ovaries, and uterus." | 1.38 | [A case of advanced gastric cancer successfully treated with docetaxel and S-1 combined therapy]. ( Hasegawa, H; Kubo, H; Miyahara, M; Nishiyama, M; Tada, K; Yamashita, Y, 2012) |
| "When treating advanced and metastatic breast cancer patients with chemotherapy, it is mandatory to maintain the patients quality of life while keeping an acceptable level of antitumor activity." | 1.37 | [Chemotherapy of a 2-week S-1 administration followed by 1-week rest for advanced and metastatic breast cancer]. ( Akizuki, M; Fujii, K; Fukutomi, T; Kobayashi, K; Kosaka, J; Mouri, Y; Nakano, S; Yorozuya, K; Yoshida, M, 2011) |
| "Thymic carcinoma is a rare intrathoracic malignant tumor, and the prognosis for patients with advanced stage of the disease is poor." | 1.36 | S-1 is an active anticancer agent for advanced thymic carcinoma. ( Hosomi, Y; Iguchi, M; Okamura, T; Okuma, Y; Shibuya, M; Shimokawa, T; Takagi, Y, 2010) |
| "The outcome of stage III gastric cancer patients treated by D2 dissection followed by adjuvant chemotherapy with S-1 remains unsatisfactory." | 1.36 | A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). ( Ishiyama, A; Ito, H; Ito, S; Kinoshita, T; Kodera, Y; Mochizuki, Y; Nakao, A; Sakamoto, J; Tsuburaya, A; Yokoyama, H; Yoshikawa, T, 2010) |
| "We present here a case of interstitial pneumonitis that occurred after S-1 treatment." | 1.36 | [A case of interstitial pneumonitis induced by S-1]. ( Kanematsu, S; Kasahara, N; Kwon, AH; Nakatake, R; Okukawa, H; Shoji, T; Tanaka, K; Ueyama, Y; Yamamoto, D; Yoshida, H, 2010) |
| "CT demonstrated liver(S5/6)and lung(S9)metastases in August 2002." | 1.36 | [A case of long-term survival after undergoing S-1 treatment and splenectomy for liver, lung and splenic metastases following curative distal gastrectomy for gastric cancer]. ( Furuya, T; Hirao, H; Nagai, M; Nakamura, H; Nomura, Y; Ogura, M; Suzuki, Y; Takahashi, M; Takayama, T; Tanaka, N, 2010) |
| "We experienced 3 cases of recurrent breast cancer treated with S-1 therapy, delaying tumor progression and improving their quality of life (QOL)." | 1.36 | [Three cases of metastatic breast cancer effectively treated with S-1 therapy]. ( Kaisaki, S; Kato, M; Kitayama, J; Nagawa, H; Sanuki, J; Yamaguchi, H, 2010) |
| "Due to paraaortic lymph node metastasis (#16a1, #16a2) and peritoneal metastasis, total gastrectomy and D0 lymph node dissection were performed." | 1.35 | [Long-term survival case of advanced gastric cancer with paraaortic lymph node metastasis and peritoneal metastasis from S-1/CDDP combination therapy after reductive operation]. ( Akagi, J; Fukami, K; Masuda, Y; Takai, E; Takemoto, T; Yagishita, Y, 2008) |
| "For treatment of recurrent breast carcinoma, S-1 is considered to be a useful and tolerable anticancer drug, and combination treatment of S-1 and ZOL is thought to be effective." | 1.35 | [A case of recurrent breast carcinoma metastasis successfully treated with S-1 and zoledronic acid therapy]. ( Arita, K; Hiranuma, S; Kuramochi, J; Kurokawa, T; Matsumoto, A; Sanada, K; Takiguchi, N; Tanaka, Y; Usui, S, 2009) |
| " Long-term administration of S-1 may serve to prolong the survival period of patients with gastric cancer after reduction surgery, particularly in peritoneal metastasis." | 1.34 | [Clinical study of S-1 for advanced gastric cancer after reduction surgery]. ( Hayashi, K; Inaba, Y; Isobe, H; Miura, T; Moriya, T; Takiguchi, M; Watabe, S, 2007) |
| "Under the diagnosis of multiple lung metastases, the patient was hospitalized and received intensive chemotherapy with docetaxel 40 mg/week (day 1), 5-fluorouracil 500 mg/day (days 1-5), cisplatin 10 mg/day (days 1-5)." | 1.33 | A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy. ( Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T, 2006) |
| "Since metastases to the liver, left adrenal gland, and Douglas' pouch were detected in addition to ascites and bilateral hydronephrosis, the tumor was judged unresectable and systemic chemotherapy with TS-1 was begun." | 1.31 | [A case in which TS-1, an orally-administered 5-FU chemotherapeutic agent, showed marked effectiveness against scirrhous type gastric cancer with multiple organ metastases]. ( Araki, S; Asakura, R; Itou, A; Kobayashi, K; Naganuma, J; Teruya, M; Yanagida, O, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.59) | 18.2507 |
| 2000's | 31 (18.34) | 29.6817 |
| 2010's | 129 (76.33) | 24.3611 |
| 2020's | 8 (4.73) | 2.80 |
| Authors | Studies |
|---|---|
| Mukai, H | 5 |
| Uemura, Y | 3 |
| Akabane, H | 1 |
| Watanabe, T | 4 |
| Park, Y | 1 |
| Takahashi, M | 4 |
| Sagara, Y | 2 |
| Nishimura, R | 3 |
| Takashima, T | 4 |
| Fujisawa, T | 1 |
| Hozumi, Y | 4 |
| Kawahara, T | 3 |
| Takumoto, Y | 1 |
| Sasahara, Y | 1 |
| Narimatsu, H | 1 |
| Akazawa, M | 1 |
| Kobayashi, D | 1 |
| Ishigami, H | 1 |
| Kanda, M | 1 |
| Tanaka, C | 3 |
| Yamaguchi, H | 2 |
| Kitayama, J | 2 |
| Kodera, Y | 4 |
| Okuma, Y | 3 |
| Goto, Y | 1 |
| Ohyanagi, F | 1 |
| Sunami, K | 1 |
| Nakahara, Y | 1 |
| Kitazono, S | 1 |
| Kudo, K | 2 |
| Tambo, Y | 1 |
| Kanda, S | 1 |
| Yanagitani, N | 1 |
| Horiike, A | 1 |
| Horinouchi, H | 1 |
| Fujiwara, Y | 2 |
| Nokihara, H | 1 |
| Yamamoto, N | 1 |
| Nishio, M | 1 |
| Ohe, Y | 1 |
| Hosomi, Y | 3 |
| Inoue, H | 1 |
| Todaka, A | 1 |
| Yamazaki, K | 4 |
| Fushiki, K | 1 |
| Shirasu, H | 1 |
| Kawakami, T | 1 |
| Tsushima, T | 1 |
| Hamauchi, S | 1 |
| Yokota, T | 1 |
| Machida, N | 2 |
| Fukutomi, A | 4 |
| Onozawa, Y | 2 |
| Andoh, A | 1 |
| Yasui, H | 3 |
| Miki, M | 1 |
| Takao, S | 1 |
| Konishi, M | 1 |
| Shigeoka, Y | 1 |
| Miyashita, M | 1 |
| Suwa, H | 1 |
| Miyoshi, Y | 3 |
| Hirokaga, K | 1 |
| Okuno, T | 2 |
| Yamagami, K | 1 |
| Imamura, M | 1 |
| Murase, K | 1 |
| Yanai, A | 1 |
| Tanino, H | 1 |
| Denda, T | 3 |
| Takashima, A | 1 |
| Gamoh, M | 2 |
| Iwanaga, I | 1 |
| Komatsu, Y | 2 |
| Nakamura, M | 3 |
| Ohori, H | 1 |
| Sakashita, A | 1 |
| Tsuda, M | 2 |
| Kobayashi, Y | 1 |
| Baba, H | 8 |
| Kotake, M | 1 |
| Ishioka, C | 1 |
| Yamada, Y | 6 |
| Sato, A | 4 |
| Yuki, S | 1 |
| Morita, S | 7 |
| Takahashi, S | 2 |
| Yamaguchi, T | 9 |
| Shimada, K | 4 |
| Kumagai, T | 2 |
| Kimura, M | 3 |
| Inoue, T | 1 |
| Tamiya, M | 1 |
| Nishino, K | 2 |
| Imamura, F | 2 |
| Nagakawa, Y | 1 |
| Hosokawa, Y | 1 |
| Nakayama, H | 1 |
| Sahara, Y | 1 |
| Takishita, C | 1 |
| Nakajima, T | 3 |
| Hijikata, Y | 1 |
| Kasuya, K | 1 |
| Katsumata, K | 1 |
| Tokuuye, K | 1 |
| Tsuchida, A | 1 |
| Mukai, T | 1 |
| Uehara, K | 1 |
| Goto, H | 1 |
| Hiramatsu, K | 1 |
| Kobayashi, S | 1 |
| Sakamoto, E | 1 |
| Maeda, A | 1 |
| Takeuchi, E | 1 |
| Okada, Y | 2 |
| Ebata, T | 1 |
| Nagino, M | 1 |
| Hamada, C | 2 |
| Okusaka, T | 7 |
| Ikari, T | 1 |
| Isayama, H | 2 |
| Furuse, J | 6 |
| Ishii, H | 4 |
| Nakai, Y | 1 |
| Imai, S | 1 |
| Okamura, S | 1 |
| Kitamura, S | 2 |
| Tanahashi, T | 1 |
| Aoyagi, E | 1 |
| Nakagawa, T | 2 |
| Okamoto, K | 3 |
| Kimura, T | 2 |
| Miyamoto, H | 3 |
| Mitsui, Y | 2 |
| Rokutan, K | 1 |
| Muguruma, N | 2 |
| Takayama, T | 5 |
| Toyokawa, T | 1 |
| Tamura, T | 1 |
| Shibutani, M | 1 |
| Ohira, G | 1 |
| Yamazoe, S | 1 |
| Kimura, K | 2 |
| Nagahara, H | 2 |
| Amano, R | 2 |
| Tanaka, H | 2 |
| Muguruma, K | 2 |
| Yashiro, M | 1 |
| Hirakawa, K | 2 |
| Ohira, M | 2 |
| Kitani, Y | 2 |
| Kubota, A | 2 |
| Furukawa, M | 1 |
| Hori, Y | 1 |
| Nakayama, Y | 1 |
| Nonaka, T | 1 |
| Mizoguchi, N | 1 |
| Hatakeyama, H | 1 |
| Oridate, N | 1 |
| Li, J | 2 |
| Xu, R | 1 |
| Xu, J | 1 |
| Ikejiri, K | 1 |
| Shen, L | 1 |
| Toh, Y | 2 |
| Kato, T | 4 |
| Sakai, K | 1 |
| Yamamoto, M | 2 |
| Mishima, H | 3 |
| Wang, J | 4 |
| Ajani, JA | 1 |
| Abramov, M | 1 |
| Bondarenko, I | 1 |
| Shparyk, Y | 1 |
| Gorbunova, V | 1 |
| Hontsa, A | 1 |
| Otchenash, N | 1 |
| Alsina, M | 1 |
| Lazarev, S | 1 |
| Feliu, J | 1 |
| Elme, A | 1 |
| Esko, V | 1 |
| Abdalla, K | 1 |
| Verma, U | 1 |
| Benedetti, F | 1 |
| Aoyama, T | 2 |
| Mizuguchi, H | 1 |
| Makris, L | 1 |
| Rosati, G | 1 |
| Chen, J | 2 |
| Wu, X | 2 |
| Che, X | 1 |
| Zou, Y | 1 |
| Weng, M | 1 |
| Miao, Q | 1 |
| Zheng, Q | 1 |
| Hagiwara, Y | 2 |
| Shiroiwa, T | 2 |
| Shimozuma, K | 2 |
| Taira, N | 1 |
| Fukuda, T | 2 |
| Ohashi, Y | 6 |
| Mouri, M | 1 |
| Ohsumi, S | 1 |
| Ina, K | 1 |
| Furuta, R | 1 |
| Yoo, C | 1 |
| Han, B | 3 |
| Kim, HS | 6 |
| Kim, KP | 2 |
| Kim, D | 1 |
| Jeong, JH | 1 |
| Lee, JL | 3 |
| Kim, TW | 4 |
| Kim, JH | 9 |
| Choi, DR | 3 |
| Ha, HI | 2 |
| Seo, J | 1 |
| Chang, HM | 3 |
| Ryoo, BY | 1 |
| Zang, DY | 4 |
| Matsuda, C | 1 |
| Honda, M | 1 |
| Kondo, K | 1 |
| Takahashi, T | 9 |
| Kosugi, C | 1 |
| Tokunaga, Y | 1 |
| Takemoto, H | 2 |
| Kim, HM | 1 |
| Sakamoto, J | 5 |
| Oba, K | 1 |
| Zhu, H | 1 |
| Yi, C | 2 |
| Zhao, Y | 1 |
| Gou, H | 1 |
| Qiao, G | 1 |
| Wang, X | 2 |
| Zhou, L | 1 |
| Zhou, X | 1 |
| Song, Y | 1 |
| Wang, S | 1 |
| Zhao, L | 1 |
| Morse, MA | 1 |
| Hobeika, A | 1 |
| Song, J | 1 |
| Yi, X | 1 |
| Xia, X | 1 |
| Ren, J | 1 |
| Lyerly, HK | 1 |
| Chen, Y | 2 |
| Wu, J | 1 |
| Cheng, K | 1 |
| Li, ZP | 1 |
| Luo, DY | 2 |
| Qiu, M | 1 |
| Gou, HF | 1 |
| Li, Q | 2 |
| Yang, Y | 2 |
| Cao, D | 1 |
| Shen, YL | 1 |
| Bi, F | 1 |
| Liu, JY | 1 |
| Endo, S | 2 |
| Kurokawa, Y | 3 |
| Kimura, Y | 1 |
| Matsuyama, J | 1 |
| Taniguchi, H | 2 |
| Takeno, A | 1 |
| Kawabata, R | 1 |
| Kawada, J | 1 |
| Masuzawa, T | 1 |
| Yamamoto, K | 1 |
| Kobayashi, K | 5 |
| Sakai, D | 2 |
| Shimokawa, T | 2 |
| Satoh, T | 4 |
| Kojima, Y | 1 |
| Yoshie, R | 1 |
| Kawamoto, H | 1 |
| Shimo, A | 1 |
| Uejima, T | 1 |
| Iwatani, T | 1 |
| Motoyoshi, A | 1 |
| Kanemaki, Y | 1 |
| Boku, N | 8 |
| Tsugawa, K | 1 |
| Meng, M | 1 |
| Ye, X | 1 |
| Yang, X | 1 |
| Huang, G | 1 |
| Wei, Z | 1 |
| Ni, Y | 1 |
| Li, W | 1 |
| Han, X | 1 |
| Moriwaki, T | 3 |
| Sakai, Y | 1 |
| Ishida, H | 1 |
| Yamamoto, Y | 2 |
| Kuramochi, H | 2 |
| Sato, M | 2 |
| Hatachi, Y | 1 |
| Bando, Y | 1 |
| Maeba, T | 1 |
| Ikezawa, K | 1 |
| Shimada, M | 1 |
| Amagai, K | 2 |
| Morimoto, M | 1 |
| Tsuji, A | 6 |
| Nishina, T | 4 |
| Hyodo, I | 6 |
| Ohno, S | 1 |
| Narui, K | 1 |
| Yoshino, H | 1 |
| Doihara, H | 1 |
| Suto, A | 1 |
| Tamura, M | 1 |
| Morimoto, T | 2 |
| Zaha, H | 1 |
| Chishima, T | 1 |
| Ishikawa, T | 1 |
| Wakasaki, T | 1 |
| Yasumatsu, R | 1 |
| Uchi, R | 1 |
| Taura, M | 1 |
| Matsuo, M | 1 |
| Komune, N | 1 |
| Xu, T | 1 |
| Ueno, H | 4 |
| Ioka, T | 1 |
| Ikeda, M | 5 |
| Ohkawa, S | 4 |
| Yanagimoto, H | 3 |
| Sugimori, K | 1 |
| Yamao, K | 3 |
| Shimamura, T | 1 |
| Sho, M | 2 |
| Kitano, M | 1 |
| Cheng, AL | 2 |
| Mizumoto, K | 2 |
| Chen, JS | 2 |
| Funakoshi, A | 4 |
| Hatori, T | 1 |
| Egawa, S | 2 |
| Tanaka, M | 1 |
| Suzuki, Y | 2 |
| Ogiya, R | 1 |
| Oshitanai, R | 1 |
| Terao, M | 1 |
| Terada, M | 1 |
| Morioka, T | 1 |
| Tsuda, B | 1 |
| Niikura, N | 1 |
| Okamura, T | 3 |
| Saito, Y | 1 |
| Tokuda, Y | 1 |
| Yunokawa, M | 1 |
| Katsumata, N | 1 |
| Yamamoto, H | 4 |
| Kodaira, M | 1 |
| Yonemori, K | 1 |
| Shimizu, C | 1 |
| Ando, M | 2 |
| Tamura, K | 1 |
| Chen, L | 2 |
| Song, MQ | 1 |
| Lin, HZ | 1 |
| Hao, LH | 1 |
| Jiang, XJ | 1 |
| Li, ZY | 1 |
| Chen, YX | 1 |
| Hirai, S | 1 |
| Hironaka, S | 2 |
| Soeda, A | 1 |
| Nihei, T | 2 |
| Hirose, M | 1 |
| Matsuda, K | 1 |
| Ohkawara, A | 1 |
| Ozeki, M | 1 |
| Mamiya, T | 1 |
| Murashita, T | 1 |
| Mochizuki, Y | 2 |
| Ohashi, N | 2 |
| Kojima, H | 1 |
| Ishigure, K | 1 |
| Kinoshita, T | 3 |
| Eguchi, T | 1 |
| Fujitake, S | 1 |
| Ito, S | 2 |
| Fujiwara, M | 2 |
| Kim, SY | 4 |
| S Hong, Y | 1 |
| K Shim, E | 1 |
| Kong, SY | 4 |
| Shin, A | 1 |
| Baek, JY | 2 |
| Jung, KH | 3 |
| Song, H | 2 |
| Park, CK | 2 |
| Jeon, JY | 2 |
| Kim, IG | 1 |
| Kim, HJ | 4 |
| Jung, JY | 3 |
| Kwon, JH | 3 |
| Jang, G | 1 |
| Kim, HY | 3 |
| Park, SR | 5 |
| Hong, YS | 4 |
| Lim, HS | 1 |
| Seong, MW | 1 |
| Park, YI | 3 |
| Shibata, T | 1 |
| Sasako, M | 2 |
| Sano, T | 1 |
| Tsuburaya, A | 3 |
| Iwasaki, Y | 1 |
| Fukuda, H | 1 |
| Horiguchi, J | 1 |
| Takata, D | 1 |
| Rokutanda, N | 1 |
| Nagaoka, R | 1 |
| Tokiniwa, H | 1 |
| Odawara, H | 1 |
| Kikuchi, M | 1 |
| Takeyoshi, I | 1 |
| Noso, Y | 1 |
| Yamagata, S | 1 |
| Horie, T | 1 |
| Ishibashi, Y | 1 |
| Yamaue, H | 1 |
| Satoi, S | 1 |
| Kanbe, T | 1 |
| Miyazawa, M | 1 |
| Tani, M | 1 |
| Kawai, M | 1 |
| Hirono, S | 1 |
| Okada, K | 2 |
| Kwon, AH | 2 |
| Mukouyama, T | 1 |
| Tsunoda, H | 1 |
| Chijiiwa, K | 1 |
| Ohuchida, J | 1 |
| Kato, J | 3 |
| Ueda, K | 1 |
| Hayashi, K | 4 |
| Shirasaka, T | 2 |
| Mizushima, T | 2 |
| Ide, Y | 1 |
| Murata, K | 1 |
| Ohashi, I | 1 |
| Yasumasa, K | 1 |
| Fukunaga, M | 2 |
| Tamagawa, H | 1 |
| Hasegawa, J | 1 |
| Hata, T | 2 |
| Takemasa, I | 2 |
| Sekimoto, M | 1 |
| Nezu, R | 1 |
| Doki, Y | 2 |
| Mori, M | 3 |
| Sudo, K | 2 |
| Ishihara, T | 2 |
| Hirata, N | 1 |
| Ozawa, F | 1 |
| Ohshima, T | 1 |
| Azemoto, R | 1 |
| Shimura, K | 1 |
| Nishino, T | 1 |
| Nakagawa, A | 1 |
| Nakamura, K | 2 |
| Hara, T | 2 |
| Tada, M | 1 |
| Mikata, R | 1 |
| Tawada, K | 1 |
| Yokosuka, O | 2 |
| Nakaji, S | 1 |
| Koizumi, W | 2 |
| Kim, YH | 1 |
| Fujii, M | 3 |
| Kim, HK | 2 |
| Imamura, H | 2 |
| Lee, KH | 4 |
| Chung, HC | 2 |
| Cho, JY | 1 |
| Hosaka, H | 1 |
| Takagane, A | 2 |
| Inokuchi, M | 1 |
| Tanabe, K | 2 |
| Ogura, M | 2 |
| Yoshida, K | 5 |
| Takeuchi, M | 2 |
| Nagahama, T | 1 |
| Seki, R | 1 |
| Fujiya, K | 1 |
| Amagasa, H | 1 |
| Takasaki, J | 1 |
| Kamikozuru, H | 1 |
| Ganno, H | 1 |
| Ami, K | 1 |
| Fukuda, A | 1 |
| Arai, K | 2 |
| Tei, S | 1 |
| Nakashima, H | 1 |
| Abe, T | 1 |
| Ensako, T | 1 |
| Hino, K | 1 |
| Nakayama, T | 2 |
| Yoshidome, K | 2 |
| Kawajiri, H | 1 |
| Kamigaki, S | 2 |
| Tsurutani, J | 2 |
| Arai, T | 1 |
| Ito, T | 2 |
| Komoike, Y | 2 |
| Doi, T | 3 |
| Masuda, N | 2 |
| Miyauchi, K | 1 |
| Taguchi, T | 6 |
| Miyamoto, Y | 1 |
| Sakamoto, Y | 1 |
| Yoshida, N | 1 |
| Peng, PJ | 1 |
| Cheng, H | 1 |
| Ou, XQ | 1 |
| Zeng, LJ | 1 |
| Liu, YM | 1 |
| Lin, Z | 1 |
| Tang, YN | 1 |
| Wang, SY | 1 |
| Zhang, HY | 1 |
| Chen, ZB | 1 |
| Aoe, K | 1 |
| Takigawa, N | 1 |
| Hotta, K | 1 |
| Maeda, T | 1 |
| Kishino, D | 1 |
| Nogami, N | 1 |
| Tabata, M | 1 |
| Harita, S | 1 |
| Okada, T | 1 |
| Kubo, T | 2 |
| Hosokawa, S | 1 |
| Fujiwara, K | 1 |
| Gemba, K | 1 |
| Yasugi, M | 1 |
| Kozuki, T | 1 |
| Kato, Y | 1 |
| Katsui, K | 1 |
| Kanazawa, S | 1 |
| Ueoka, H | 1 |
| Tanimoto, M | 1 |
| Kiura, K | 1 |
| Tanigawa, T | 2 |
| Kawano, I | 1 |
| Kuramoto, M | 1 |
| Yamamoto-Ibusuki, M | 1 |
| Iwase, H | 1 |
| Sueda, T | 1 |
| Kudo, T | 1 |
| Uemura, M | 1 |
| Nishimura, J | 1 |
| Ezoe, S | 1 |
| Matsumoto, K | 1 |
| Kim, ST | 1 |
| Lim, HY | 3 |
| Lee, J | 2 |
| Lee, KW | 1 |
| Chung, IJ | 1 |
| Cho, SH | 1 |
| Shin, SJ | 2 |
| Kang, HJ | 2 |
| Shin, DB | 2 |
| Lee, JW | 1 |
| Jo, SJ | 1 |
| Park, YS | 2 |
| Kuwano, H | 1 |
| Ojima, H | 1 |
| Otsuji, T | 1 |
| Shirao, K | 2 |
| Esaki, T | 4 |
| Ohishi, T | 1 |
| Sadahiro, S | 1 |
| Suzuki, T | 2 |
| Tanaka, A | 1 |
| Saito, G | 1 |
| Kamijo, A | 1 |
| Ishizuna, K | 1 |
| Ninomiya, J | 1 |
| Ogawa, T | 1 |
| Kojima, M | 1 |
| Tsuji, E | 1 |
| Kawashima, M | 2 |
| Nozaki, M | 1 |
| Yamagishi, H | 2 |
| Ueda, Y | 2 |
| Oh, HS | 1 |
| Cho, JW | 1 |
| Kim, MJ | 2 |
| Zhong, DT | 1 |
| Wu, RP | 1 |
| Wang, XL | 1 |
| Huang, XB | 1 |
| Lin, MX | 1 |
| Lan, YQ | 1 |
| Chen, Q | 1 |
| Sakiyama, T | 1 |
| Iwasa, T | 1 |
| Kawakami, H | 1 |
| Nonagase, Y | 1 |
| Yoshida, T | 2 |
| Tanaka, K | 4 |
| Fujisaka, Y | 1 |
| Kurata, T | 1 |
| Nishio, K | 1 |
| Nakagawa, K | 1 |
| Tsukahara, K | 1 |
| Hasegawa, Y | 1 |
| Takemura, H | 1 |
| Terada, T | 1 |
| Nagahara, K | 1 |
| Nakatani, H | 1 |
| Yoshino, K | 1 |
| Higaki, Y | 1 |
| Iwae, S | 1 |
| Beppu, T | 1 |
| Hanamure, Y | 1 |
| Tomita, K | 1 |
| Kohno, N | 1 |
| Kawabata, K | 1 |
| Fukushima, M | 5 |
| Teramukai, S | 2 |
| Yoshida, M | 4 |
| Muro, K | 3 |
| Hamamoto, Y | 2 |
| Yoshino, T | 4 |
| Miyata, Y | 3 |
| Takahari, D | 2 |
| Ohtsu, A | 4 |
| Motoi, F | 1 |
| Unno, M | 2 |
| Yamaguchi, K | 4 |
| Nagase, M | 2 |
| Nakamori, S | 2 |
| Tsuchiya, Y | 1 |
| Omuro, Y | 1 |
| Matsumoto, S | 3 |
| Yamada, N | 1 |
| Ichikawa, Y | 3 |
| Watanabe, G | 1 |
| Wakabayashi, G | 1 |
| Egawa, N | 1 |
| Hosotani, R | 1 |
| Shigekawa, T | 1 |
| Osaki, A | 1 |
| Sekine, H | 1 |
| Sato, N | 1 |
| Kanbayashi, C | 1 |
| Sano, H | 1 |
| Takeuchi, H | 2 |
| Ueda, S | 1 |
| Nakamiya, N | 1 |
| Sugitani, I | 1 |
| Sugiyama, M | 1 |
| Shimada, H | 1 |
| Hirokawa, E | 1 |
| Saeki, T | 1 |
| Takahashi, K | 1 |
| Sasaki, Y | 3 |
| Watanabe, M | 1 |
| Sakata, Y | 2 |
| Shimada, Y | 4 |
| Sugihara, K | 1 |
| Jiang, H | 1 |
| Qian, J | 1 |
| Zhao, P | 1 |
| Zhang, X | 2 |
| Zheng, Y | 2 |
| Mao, C | 1 |
| Wang, Y | 2 |
| Mou, H | 1 |
| Fang, W | 1 |
| Teng, L | 1 |
| Xu, N | 2 |
| Katakami, N | 2 |
| Hata, A | 2 |
| Okuda, C | 1 |
| Urata, Y | 1 |
| Hattori, Y | 1 |
| Tachihara, M | 1 |
| Yokota, S | 1 |
| Nishimura, T | 3 |
| Kaneda, T | 1 |
| Satouchi, M | 1 |
| Negoro, S | 1 |
| Chua, C | 1 |
| Tan, IB | 1 |
| Rha, SY | 2 |
| Yong, WP | 1 |
| Ong, WS | 1 |
| Tham, CK | 1 |
| Ng, M | 1 |
| Tai, DW | 1 |
| Iwasa, S | 3 |
| Choo, SP | 1 |
| Sato, Y | 4 |
| Fujino, Y | 1 |
| Takaoka, T | 2 |
| Miyoshi, J | 1 |
| Kagawa, M | 1 |
| Ohnuma, H | 2 |
| Hirakawa, M | 1 |
| Osuga, T | 1 |
| Sagawa, T | 2 |
| Takahashi, Y | 2 |
| Katsuki, S | 1 |
| Okuda, T | 1 |
| Takimoto, R | 2 |
| Kobune, M | 2 |
| Nobuoka, T | 1 |
| Hirata, K | 2 |
| Wada, K | 1 |
| Sano, K | 1 |
| Amano, H | 1 |
| Miura, F | 1 |
| Toyota, N | 1 |
| Ito, H | 2 |
| Shibuya, M | 3 |
| Ikeda, Y | 1 |
| Kainuma, M | 1 |
| Takada, T | 1 |
| Yata, Y | 1 |
| Yonenaga, Y | 1 |
| Hanaki, K | 1 |
| Mise, M | 1 |
| Higaside, S | 1 |
| Kanda, Y | 1 |
| Noda, H | 1 |
| Nagashima, K | 1 |
| Matsumoto, H | 3 |
| Goto, A | 4 |
| Kato, K | 6 |
| Okita, NT | 1 |
| Matoda, M | 1 |
| Yamamoto, A | 1 |
| Nomura, H | 1 |
| Okamoto, S | 1 |
| Sakamoto, K | 2 |
| Kondo, E | 1 |
| Omatsu, K | 1 |
| Takeshima, N | 1 |
| Komori, A | 1 |
| Narita, Y | 1 |
| Nitta, S | 1 |
| Nomura, M | 1 |
| Kadowaki, S | 1 |
| Ura, T | 1 |
| Andoh, M | 1 |
| Mori, K | 1 |
| Igarashi, Y | 1 |
| Wang, ZQ | 1 |
| Zhang, DS | 1 |
| Deng, YH | 1 |
| Wang, FH | 1 |
| Luo, HY | 1 |
| Qiu, MZ | 1 |
| Li, YH | 1 |
| Xu, RH | 1 |
| Abdel-Rahman, O | 1 |
| ElHalawani, H | 1 |
| Miyamoto, S | 1 |
| Hishima, T | 1 |
| Miyata, R | 1 |
| Kameyama, N | 1 |
| Tomita, M | 1 |
| Mitsuhashi, H | 1 |
| Baba, S | 1 |
| Amada, E | 1 |
| Miyake, Y | 1 |
| Nagata, N | 1 |
| Ogata, Y | 2 |
| Otsuka, K | 2 |
| Kagimura, T | 1 |
| Shimoyama, R | 1 |
| Kawamoto, S | 1 |
| Goda, F | 1 |
| Negoro, Y | 1 |
| Yoshizaki, K | 1 |
| Goji, T | 1 |
| Yano, H | 1 |
| Okahisa, T | 1 |
| Niitsu, Y | 2 |
| Emi, Y | 1 |
| Oki, E | 1 |
| Shimokawa, M | 1 |
| Tanaka, T | 1 |
| Akagi, Y | 1 |
| Natsugoe, S | 1 |
| Maehara, Y | 1 |
| Weidong, C | 1 |
| Lijun, X | 1 |
| Dai, X | 1 |
| Wang, C | 1 |
| Jiang, J | 1 |
| Wu, C | 1 |
| Lee, DW | 1 |
| Im, SA | 2 |
| Kim, YJ | 1 |
| Rhee, J | 3 |
| Na, II | 1 |
| Kim, TY | 4 |
| Han, SW | 2 |
| Choi, IS | 2 |
| Oh, DY | 2 |
| Bang, YJ | 2 |
| Park, SH | 2 |
| Kim, YS | 1 |
| Hong, J | 2 |
| Park, J | 1 |
| Nam, E | 1 |
| Cho, EK | 1 |
| Lee, JH | 4 |
| Lee, WK | 1 |
| Chung, M | 1 |
| Yin, J | 1 |
| Zhu, X | 1 |
| Liu, Y | 1 |
| Cao, J | 1 |
| Lu, F | 1 |
| Zuo, Y | 1 |
| Kim, BC | 1 |
| Park, JW | 1 |
| Choi, HS | 1 |
| Jeong, SY | 1 |
| Kim, DY | 1 |
| Hong, CW | 1 |
| Sohn, DK | 1 |
| Tanaka, Y | 1 |
| Kurokawa, T | 1 |
| Arita, K | 1 |
| Kuramochi, J | 1 |
| Usui, S | 1 |
| Matsumoto, A | 1 |
| Takiguchi, N | 1 |
| Hiranuma, S | 1 |
| Sanada, K | 1 |
| Lee, GW | 1 |
| Ju, JH | 1 |
| Kim, SH | 2 |
| Kim, HG | 1 |
| Kim, TH | 1 |
| Jeong, CY | 1 |
| Kang, JH | 1 |
| Lee, BH | 1 |
| Park, HC | 1 |
| Song, HH | 1 |
| Hwang, SW | 1 |
| Park, CH | 1 |
| Kim, KO | 1 |
| Jang, KM | 1 |
| Taku, K | 1 |
| Kojima, T | 2 |
| Baba, E | 2 |
| Fujishima, H | 2 |
| Kusaba, H | 2 |
| Ariyama, H | 2 |
| Tanaka, R | 1 |
| Mitsugi, K | 2 |
| Shibata, Y | 1 |
| Harada, M | 1 |
| Nakano, S | 3 |
| Nanjo, S | 1 |
| Kida, Y | 1 |
| Higashi, Y | 1 |
| Kaji, R | 1 |
| Fujita, S | 1 |
| Park, MJ | 1 |
| Uhm, JE | 1 |
| Lee, Y | 1 |
| Lee, HY | 1 |
| Kang, EM | 1 |
| Park, JO | 1 |
| Kang, WK | 1 |
| Sawaki, A | 1 |
| Furuhata, T | 1 |
| Miyashita, K | 1 |
| Okubo, S | 1 |
| Shintani, N | 1 |
| Tanaka, S | 1 |
| Kida, M | 1 |
| Ohta, H | 1 |
| Miyanishi, K | 1 |
| Sato, T | 3 |
| Yanagihara, K | 2 |
| Yoshimura, K | 2 |
| Niimi, M | 2 |
| Yasuda, H | 1 |
| Sasaki, T | 1 |
| Ishiguro, H | 1 |
| Kitano, T | 1 |
| Kanai, M | 2 |
| Misawa, A | 1 |
| Tada, H | 1 |
| Mio, T | 1 |
| Harada, H | 1 |
| Omura, K | 1 |
| Kim, JY | 1 |
| Do, YR | 1 |
| Park, KU | 1 |
| Kim, JG | 1 |
| Chae, YS | 1 |
| Kim, MK | 1 |
| Ryoo, HM | 1 |
| Bae, SH | 1 |
| Baek, JH | 1 |
| Song, HS | 1 |
| Murakami, S | 1 |
| Mitsuyama, S | 1 |
| Ohmura, T | 1 |
| Yajima, T | 1 |
| Tokumoto, N | 1 |
| Ohdan, H | 1 |
| Kato, M | 1 |
| Sanuki, J | 1 |
| Kaisaki, S | 1 |
| Nagawa, H | 1 |
| Tahara, M | 2 |
| Araki, K | 1 |
| Okano, S | 1 |
| Kiyota, N | 1 |
| Fuse, N | 1 |
| Minashi, K | 2 |
| Zenda, S | 1 |
| Ogino, T | 1 |
| Hayashi, R | 1 |
| Minami, H | 1 |
| Strumberg, D | 1 |
| Bergmann, L | 1 |
| Graeven, U | 1 |
| Hanauske, A | 1 |
| Lipp, R | 1 |
| Schuette, J | 1 |
| Schultheis, B | 1 |
| Scigalla, P | 1 |
| Urrea, P | 1 |
| Scheulen, ME | 1 |
| Tanaka, N | 1 |
| Furuya, T | 1 |
| Nomura, Y | 1 |
| Nagai, M | 1 |
| Hirao, H | 1 |
| Nakamura, H | 1 |
| Chao, Y | 1 |
| Hsieh, RK | 1 |
| Chen, PM | 1 |
| Chiou, TJ | 1 |
| Chao, TY | 1 |
| Yeh, KH | 1 |
| Chen, LT | 1 |
| Whang-Peng, J | 1 |
| Ueyama, Y | 1 |
| Yamamoto, D | 3 |
| Yoshida, H | 3 |
| Kanematsu, S | 2 |
| Nakatake, R | 1 |
| Kasahara, N | 1 |
| Shoji, T | 1 |
| Okukawa, H | 1 |
| Ham, HS | 1 |
| Kim, BS | 1 |
| Kang, GH | 1 |
| Kunisaki, C | 1 |
| Makino, H | 1 |
| Oshima, T | 1 |
| Fujii, S | 1 |
| Takagawa, R | 1 |
| Kimura, J | 1 |
| Kosaka, T | 1 |
| Ono, HA | 1 |
| Akiyama, H | 1 |
| Kameda, K | 1 |
| Kito, F | 1 |
| Endo, I | 1 |
| Tsumura, T | 1 |
| Asada, M | 1 |
| Suzuki, C | 1 |
| Nitta, T | 1 |
| Yasuchika, K | 1 |
| Taura, K | 1 |
| Mori, Y | 1 |
| Hamada, A | 1 |
| Inoue, N | 1 |
| Tada, S | 1 |
| Yazumi, S | 1 |
| Osaki, Y | 1 |
| Chiba, T | 1 |
| Ikai, I | 1 |
| Uemoto, S | 1 |
| Hatano, E | 1 |
| Ichikawa, D | 1 |
| Otsuji, E | 1 |
| Morii, J | 1 |
| Koizumi, K | 1 |
| Kakihara, N | 1 |
| Shimotsuma, M | 1 |
| Yamashita, T | 2 |
| Taniguchi, F | 1 |
| Aragane, H | 1 |
| Nishi, H | 1 |
| Itokawa, Y | 1 |
| Ishiyama, A | 1 |
| Yoshikawa, T | 2 |
| Yokoyama, H | 2 |
| Nakao, A | 2 |
| Ryu, KW | 3 |
| Kim, YW | 3 |
| Choi, IJ | 3 |
| Kim, CG | 3 |
| Lee, JY | 2 |
| Cho, SJ | 2 |
| Kim, NK | 3 |
| Iwase, S | 1 |
| Kuroda, Y | 1 |
| Yamamoto, C | 1 |
| Kitamura, K | 1 |
| Odagiri, H | 1 |
| Nagumo, Y | 1 |
| Takagi, Y | 1 |
| Iguchi, M | 1 |
| Morikita, T | 1 |
| Akashi, K | 1 |
| Ah, K | 1 |
| Choi, YH | 1 |
| Lee, SS | 1 |
| Ryu, MH | 2 |
| Kang, YK | 2 |
| Nam, BH | 1 |
| Nakayama, G | 1 |
| Okuda, N | 1 |
| Iwata, N | 1 |
| Koike, M | 1 |
| Mizukami, T | 1 |
| Kamiyama, T | 1 |
| Nakanishi, K | 1 |
| Taniguchi, M | 1 |
| Yokoo, H | 1 |
| Kakisaka, T | 1 |
| Kamachi, H | 1 |
| Matsushita, M | 1 |
| Todo, S | 1 |
| Jung, M | 1 |
| Jeung, HC | 1 |
| Kim, HR | 2 |
| Roh, JK | 1 |
| Ahn, JB | 1 |
| Sandler, A | 1 |
| Graham, C | 1 |
| Baggstrom, M | 1 |
| Herbst, R | 1 |
| Zergebel, C | 1 |
| Saito, K | 1 |
| Jones, D | 1 |
| Moriyasu, F | 1 |
| Kikuchi, D | 1 |
| Ishii, Y | 1 |
| Saitou, M | 1 |
| Yamada, M | 1 |
| Takenoshita, S | 1 |
| Noguchi, S | 2 |
| Hamaguchi, T | 2 |
| Fujii, K | 1 |
| Kosaka, J | 1 |
| Mouri, Y | 1 |
| Yorozuya, K | 1 |
| Akizuki, M | 1 |
| Fukutomi, T | 1 |
| Sukawa, Y | 1 |
| Igarashi, H | 1 |
| Onodera, K | 1 |
| Aoki, Y | 1 |
| Suzuki, K | 1 |
| Yonezawa, K | 1 |
| Yawata, A | 1 |
| Kobayashi, T | 1 |
| Kaneto, H | 1 |
| Shimizu, H | 1 |
| Wakasugi, H | 1 |
| Matsunaga, Y | 1 |
| Itoh, M | 1 |
| Okuda, H | 1 |
| Arimura, Y | 1 |
| Shinomura, Y | 1 |
| Saze, Z | 1 |
| Hasegawa, S | 1 |
| Kanemoto, A | 1 |
| Terashima, M | 1 |
| Tahara, H | 1 |
| Hamakawa, T | 1 |
| Takiguchi, S | 1 |
| Yamasaki, M | 1 |
| Miyata, H | 1 |
| Nakajima, K | 1 |
| Dok, Y | 1 |
| Nakamura, T | 1 |
| Ota, M | 1 |
| Narumiya, K | 1 |
| Shirai, Y | 1 |
| Kubo, H | 1 |
| Nishiyama, M | 1 |
| Tada, K | 1 |
| Miyahara, M | 1 |
| Hasegawa, H | 1 |
| Yamashita, Y | 1 |
| Kitagawa, M | 1 |
| Shimura, T | 1 |
| Yamada, T | 1 |
| Ebi, M | 1 |
| Hirata, Y | 1 |
| Mizoshita, T | 1 |
| Tanida, S | 1 |
| Kataoka, H | 1 |
| Kamiya, T | 1 |
| Joh, T | 1 |
| Kim, GM | 1 |
| Koh, YW | 1 |
| Choi, EC | 1 |
| Hong, YK | 1 |
| Sung, JH | 1 |
| Kim, SM | 1 |
| Cho, BC | 1 |
| Wakisaka, N | 1 |
| Kondo, S | 1 |
| Endo, K | 1 |
| Murono, S | 1 |
| Yoshizaki, T | 1 |
| Honma, Y | 1 |
| Cui, Y | 1 |
| Yu, Y | 1 |
| Feng, Y | 1 |
| Liu, T | 1 |
| Saikawa, Y | 1 |
| Fukuda, K | 1 |
| Funakoshi, S | 1 |
| Kawakubo, H | 1 |
| Takaishi, H | 1 |
| Kitagawa, Y | 1 |
| Sakurai, K | 1 |
| Noda, E | 1 |
| Kubo, N | 1 |
| Maeda, K | 1 |
| Sawada, T | 1 |
| Goto, M | 1 |
| Kii, T | 1 |
| Nishitani, H | 1 |
| Kawabe, S | 1 |
| Kuwakado, S | 1 |
| Asaishi, K | 1 |
| Miyamoto, T | 1 |
| Higuchi, K | 1 |
| Van den Brande, J | 1 |
| Schöffski, P | 1 |
| Schellens, JH | 1 |
| Roth, AD | 1 |
| Duffaud, F | 1 |
| Weigang-Köhler, K | 1 |
| Reinke, F | 1 |
| Wanders, J | 1 |
| de Boer, RF | 1 |
| Vermorken, JB | 1 |
| Fumoleau, P | 1 |
| Ichikawa, W | 2 |
| Suto, K | 2 |
| Nihei, Z | 2 |
| Shirota, Y | 2 |
| Shimizu, M | 2 |
| Hirayama, R | 2 |
| Nukatsuka, M | 1 |
| Fujioka, A | 2 |
| Nakagawa, F | 1 |
| Oshimo, H | 1 |
| Kitazato, K | 1 |
| Uchida, J | 2 |
| Sugimoto, Y | 1 |
| Nagayama, S | 1 |
| Saek, T | 1 |
| Takashima, S | 1 |
| Sano, M | 1 |
| Horikoshi, N | 2 |
| Miura, S | 1 |
| Shimizu, S | 1 |
| Morimoto, K | 1 |
| Aoyama, H | 1 |
| Ota, J | 1 |
| Ishiguro, Y | 1 |
| Morizane, C | 2 |
| Matsubara, J | 1 |
| Nakachi, K | 2 |
| Fujitani, K | 1 |
| Narahara, H | 2 |
| Takiuchi, H | 1 |
| Tsujinaka, T | 1 |
| Satomi, E | 1 |
| Gotoh, M | 1 |
| Hirao, M | 1 |
| Furukawa, H | 2 |
| Kato, H | 1 |
| Saisho, H | 1 |
| Sugimoto, N | 1 |
| Seike, J | 1 |
| Honda, J | 1 |
| Miyoshi, T | 1 |
| Umemoto, A | 1 |
| Tangoku, A | 1 |
| Ogata, K | 1 |
| Ohchi, T | 1 |
| Doi, K | 1 |
| Matsuo, A | 1 |
| Ootao, R | 1 |
| Saito, H | 2 |
| Sohn, HJ | 1 |
| Kim, H | 1 |
| Lee, JS | 2 |
| Inaba, Y | 1 |
| Miura, T | 1 |
| Moriya, T | 1 |
| Takiguchi, M | 1 |
| Isobe, H | 1 |
| Watabe, S | 1 |
| Hosokawa, A | 1 |
| Sugiyama, T | 1 |
| Hattori, S | 1 |
| Yano, T | 1 |
| Muto, M | 1 |
| Yoshida, S | 1 |
| Sakuramoto, S | 1 |
| Nashimoto, A | 1 |
| Higashino, M | 1 |
| Yamamura, Y | 1 |
| Kurita, A | 1 |
| Akagi, J | 1 |
| Masuda, Y | 1 |
| Takai, E | 1 |
| Takemoto, T | 1 |
| Fukami, K | 1 |
| Yagishita, Y | 1 |
| Bae, JM | 1 |
| Najima, M | 1 |
| Ogura, T | 1 |
| Suzuki, E | 1 |
| Nakano, K | 1 |
| Takechi, T | 1 |
| Satake, H | 1 |
| Okabe, H | 1 |
| Oyama, K | 1 |
| Takeda, S | 1 |
| Unemi, N | 1 |
| Mitachi, Y | 1 |
| Sugimachi, K | 1 |
| Yanagida, O | 1 |
| Teruya, M | 1 |
| Itou, A | 1 |
| Naganuma, J | 1 |
| Asakura, R | 1 |
| Araki, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy[NCT01285557] | Phase 3 | 361 participants (Actual) | Interventional | 2011-04-14 | Terminated (stopped due to Due to significant changes in investigational and clinical practice landscape of frontline advanced gastric cancer, which challenged viability of trial and increased use of modified chemotherapeutic triplets led to slow participant accrual in study.) | ||
| Multicenter Phase I/IIa Study of NASOX (Nal-IRI + S-1 + Oxaliplatin) as First-line Treatment for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma[NCT04662112] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2021-06-15 | Active, not recruiting | ||
| Phase II Randomized Controlled Trial Of Dendritic Cell + Cytokine-Induced Killer Cell Immunotherapy With S-1 Versus S-1 Alone As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma Patients[NCT05955157] | Phase 2/Phase 3 | 52 participants (Anticipated) | Interventional | 2023-01-03 | Recruiting | ||
| Stereotactic Body Radiation Therapy With Sequential S-1 for Patients With Locally Advanced Pancreatic Cancer and Poor Medical Conditions --a Phase II Clinical Trial[NCT02704143] | 63 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
| Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer (With Local Progression or Metastasis)[NCT00498225] | Phase 3 | 834 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| An Open Single-center Phase II Clinical Study of Fruquintinib Combined With Chemotherapy in Patients With Liver Metastases From Pancreatic Cancer[NCT05168527] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-09-03 | Recruiting | ||
| Phase II Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas[NCT03779464] | Phase 2 | 132 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| Nivolumab as add-on to Gemcitabine/S-1 in Metastatic Pancreatic Cancer: a Phase II Trial[NCT04377048] | Phase 2 | 38 participants (Anticipated) | Interventional | 2020-07-01 | Not yet recruiting | ||
| A Phase III Study of Docetaxel and S-1 Versus S-1 in the Treatment of Advanced Gastric Cancer[NCT00287768] | Phase 3 | 628 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| A Randomized Phase III Study of SOX vs. COX in Patients With Advanced Colorectal Cancer[NCT00677443] | Phase 3 | 344 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study[NCT00336947] | Phase 3 | 500 participants (Anticipated) | Interventional | 2006-04-30 | Active, not recruiting | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| A Randomized Phase II Study of Oxaliplatin and S-1 (SOX) Versus Oxaliplatin and Capecitabine (XELOX) in Patients With Peritoneal Metastasis of Colorectal Cancer[NCT02870153] | Phase 2 | 60 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| Phase II Study of S-1 Plus Leucovorin (1 Week on and 1 Week Off) as First-line Treatment for Patients With Metastatic and Recurrent Gastric Cancer[NCT02090153] | Phase 2 | 39 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703] | Phase 2 | 38 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| [NCT01946061] | Phase 2 | 3 participants (Actual) | Interventional | 2015-05-31 | Terminated (stopped due to This study was stopped because of difficulties of supplying the drug.) | ||
| Phase III Randomized Controlled Study of Postoperative Adjuvant Therapy Using TS-1 or TS-1+PSK for Stage II or III Gastric Cancer Patients[NCT00687843] | Phase 3 | 480 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)[NCT00152217] | Phase 3 | 1,000 participants (Anticipated) | Interventional | 2001-09-30 | Completed | ||
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Prospective Multicenter Randomized Controlled Clinical Trial for Comparison Between Laparoscopic and Open Subtotal Gastrectomy With D2 Lymph Node Dissection for Locally Advanced Gastric Cancer[NCT01456598] | 1,050 participants (Actual) | Interventional | 2011-11-21 | Completed | |||
| Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection for Clinical Stage II or III Gastric Cancer[NCT02572050] | Phase 2 | 87 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| A Randomized Phase III Trial of Postoperative Chemotherapy or Chemo-radiotherapy for Locally Advanced Gastric Cancer After D2 Resection[NCT03601988] | Phase 3 | 408 participants (Anticipated) | Interventional | 2018-07-28 | Recruiting | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| Apatinib Plus S-1 for Advanced Gastric Cancer Refractory to Oxaliplatin Plus Capecitabine Combination Therapy: A Single-arm, Phase-2, Home-based Trial[NCT04338438] | Phase 2 | 37 participants (Actual) | Interventional | 2015-05-01 | Completed | ||
| A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery Using a Phase 3 [NCT03403296] | 640 participants (Actual) | Observational | 2016-07-13 | Completed | |||
| Phase III Multicenter Randomized Controlled Trial of Adjuvant Chemoradiotherapy vs Chemotherapy for Radical Resected Advanced Gastric Carcinoma Concurrent With Lymph Node Metastasis and Lymphovascular Invasion[NCT03680261] | Phase 3 | 556 participants (Anticipated) | Interventional | 2018-10-01 | Not yet recruiting | ||
| Multicenter Study on Comparison of Long-term Outcome Between Laparoscopic and Open Distal Subtotal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer[NCT01609309] | Phase 3 | 1,056 participants (Anticipated) | Interventional | 2012-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of response was defined as the time (in months) from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to <10 mm. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 5.1 |
| 5FU+Cisplatin | 4.2 |
An AE was any untoward medical condition that occurred in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication [maximum duration: 35.7 months]). (NCT01285557)
Timeframe: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| S-1+Cisplatin | 157 |
| 5FU+Cisplatin | 78 |
ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) based on the Investigator review of the images and application of Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to less than (<) 10 millimeter (mm). PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | percentage of participants (Number) |
|---|---|
| S-1+Cisplatin | 34.7 |
| 5FU+Cisplatin | 19.8 |
OS was defined as the time from randomization to the date of death for the ITT population. Participants who did not die were censored at the date last known to be alive. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From the date of randomization until disease progression or death, cut-off date: 15 August 2014 (approximately 40 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 7.5 |
| 5FU+Cisplatin | 6.6 |
PFS was defined as the time from date of randomization until date of radiological disease progression or death due to any cause. Disease Progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, where any of the 3 criteria have been met: 1) at least 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum on study, including the baseline sum, 2) Progression in no-target lesion(s), 3) appearance of new lesion(s) Participants who were alive with no PD were censored at the date of the last tumor assessment. Participants who received new anticancer therapy before disease progression were censored at the date of the last evaluable tumor assessment before new anticancer therapy was initiated. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of randomization until disease progression or death, cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 4.4 |
| 5FU+Cisplatin | 3.9 |
TTF was defined as the time from date of randomization until date of PD (clinical or radiologic), or permanent discontinuation of study treatment (S-1 or 5-FU), or death due to any cause. Participates who were still on study treatment at the time of the analysis were censored at the last date the participants was known to be on treatment. (NCT01285557)
Timeframe: From date of randomization until disease progression, cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 4.2 |
| 5FU+Cisplatin | 3.8 |
TTR was defined as the time (in months) from the date of randomization to the date of first observation of response (PR or CR) (whichever status was recorded first). TTR was assessed based on investigator assessment utilizing RECIST 1.1. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to <10 mm. PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 1.8 |
| 5FU+Cisplatin | 1.9 |
AE was defined as any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication [maximum duration: 35.7 months]). (NCT01285557)
Timeframe: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| TEAE | TESAE | |
| 5FU+Cisplatin | 111 | 31 |
| S-1+Cisplatin | 214 | 63 |
Median overall survival is calculated by Kaplan-Meier method. (NCT02704143)
Timeframe: 3 years
| Intervention | months (Median) |
|---|---|
| Combination of Cyberknife With S-1 | 14.4 |
The acute toxicities are determined by RTOG Acute Radiation Morbidity Scoring Criteria. (NCT02704143)
Timeframe: Within 90 days after completion of SBRT
| Intervention | Participants (Count of Participants) |
|---|---|
| Combination of Cyberknife With S-1 | 9 |
The late toxicities are determined by RTOG/EORTC Late Radiation Morbidity Scoring Criteria. (NCT02704143)
Timeframe: 90 days after SBRT
| Intervention | Participants (Count of Participants) |
|---|---|
| Combination of Cyberknife With S-1 | 5 |
One-year overall survival rate is calculated by the ratio of number of patients surviving more than 1 year to the total number of patients enrolled. (NCT02704143)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Combination of Cyberknife With S-1 | 46 |
Progression-free survival is the time from the date of enrollment to the confirmation of disease progression at any sites, including local progression or metastasis, or death from any causes, if this occurred before disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02704143)
Timeframe: 3 years
| Intervention | months (Median) |
|---|---|
| Combination of Cyberknife With S-1 | 10.1 |
The analysis of quality of life is based on The European Organization for Reasearch and Treatment of Cancer (EORTC): Quality of Life Questionnare-Core 30 (QLQ-C30). Higher scores in function domains and global health status indicate better quality of life, while higher scores in symptom domains imply worse quality of life. The scale range of all domains of QLQ-C30 is 0-100 (the minimum and maximum score is 0 and 100 points, respectively). (NCT02704143)
Timeframe: 1 years
| Intervention | units on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global health status | Physical functioning | Role functioning | Emotional functioning | Cognitive functioning | Social functioning | Fatigue | Nausea and vomiting | Pain | Dyspnea | Insomnia | Appetite loss | Constipation | Diarrhea | Financial difficulties | |
| Combination of Cyberknife With S-1 | 50.0 | 64.2 | 54.8 | 68.5 | 73.8 | 74.6 | 46.7 | 55.3 | 48.7 | 9.5 | 19.0 | 59.2 | 13.2 | 13.7 | 31.2 |
7 reviews available for oxonic acid and Neoplasm Metastasis
| Article | Year |
|---|---|
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Deoxyc | 2022 |
Meta-analysis for the efficacy of S-1-based regimens as the first-line treatment in Asian chemotherapy-naive patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Clinic | 2017 |
Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Disease-Free Sur | 2019 |
Efficacy of S-1 in colorectal cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother | 2014 |
S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Combinations; H | 2016 |
[A successful case of systemic chemotherapy followed by liver resection for advanced hepatocellular carcinoma with highly vascular invasion and multiple pulmonary metastases].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Combinat | 2011 |
[Combination chemotherapy of S-1 +CPT-11 (q 4-5 w) for metastatic gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Cli | 2006 |
97 trials available for oxonic acid and Neoplasm Metastasis
| Article | Year |
|---|---|
Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Combinations; D | 2021 |
Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; H | 2020 |
Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Kapl | 2020 |
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2021 |
A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteri | 2017 |
Phase II trial of neoadjuvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug | 2017 |
Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2017 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; China; Col | 2017 |
A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2017 |
Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Drug Combinations; Female; Health Status; Humans; Jap | 2018 |
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Drug Administr | 2018 |
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Diarrhea; D | 2018 |
S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Me | 2019 |
Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combination | 2019 |
Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2019 |
Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2019 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2013 |
A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2013 |
A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2014 |
CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Dose- | 2013 |
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptoth | 2013 |
Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease- | 2013 |
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydro | 2013 |
Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; H | 2014 |
[Phase I study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dru | 2013 |
Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Human | 2014 |
A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Adm | 2014 |
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2014 |
Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; | 2014 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administ | 2014 |
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2015 |
A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplas | 2015 |
Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2015 |
A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 2015 |
Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC).
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Combinations; Female; Head and N | 2015 |
Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2015 |
The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations | 2015 |
A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 2015 |
A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell | 2015 |
Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Cisplatin; Docetaxel; Drug Combinations; ErbB Recept | 2015 |
A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Dise | 2015 |
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2015 |
Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Female; Humans; | 2016 |
A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal | 2015 |
Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2016 |
A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug | 2016 |
Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2016 |
Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Diseas | 2016 |
Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study.
Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; | 2008 |
Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Femal | 2008 |
A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorect | 2009 |
Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Femal | 2009 |
Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2009 |
Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combina | 2009 |
A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2009 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2010 |
Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease | 2010 |
Preoperative concurrent chemotherapy with S-1 and radiotherapy for locally advanced squamous cell carcinoma of the oral cavity: phase I trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2010 |
Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Co | 2011 |
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Ne | 2010 |
Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Rel | 2011 |
First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group).
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Humans; Neoplasm Metastasis; Neoplasm Staging; O | 2010 |
A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Drug Combinations; Female; Huma | 2011 |
Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2011 |
Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2011 |
A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; | 2011 |
Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Confidence Interval | 2010 |
Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female | 2011 |
Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2011 |
A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2011 |
Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2011 |
A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Re | 2012 |
An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ad | 2011 |
Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplas | 2012 |
[Randomized phase II trial to compare S-1 and S-1/PSK for advanced or recurrent gastric cancer-lessons from the results].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male | 2011 |
Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2012 |
Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydroge | 2013 |
Phase I study of combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 in patients with unresectable gastric cancer (KOGC-02).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; D | 2012 |
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male | 2003 |
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male | 2003 |
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male | 2003 |
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male | 2003 |
Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); | 2004 |
A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Combinati | 2004 |
A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxyc | 2005 |
Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Rel | 2005 |
Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
Topics: Aged; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle | 2006 |
A late phase II study of S-1 for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Mal | 2008 |
Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; | 2008 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; H | 2008 |
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistanc | 2009 |
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistanc | 2009 |
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistanc | 2009 |
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistanc | 2009 |
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combi | 2000 |
65 other studies available for oxonic acid and Neoplasm Metastasis
| Article | Year |
|---|---|
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Ne | 2021 |
Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Combinations; Female; Humans; M | 2021 |
Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Drug Combinations; Female; Humans; L | 2017 |
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2017 |
[Clinical Experience of S-1 and Oxaliplatin(SOX)as the First-Line Chemotherapy for Metastatic/Recurrent Gastric Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male | 2017 |
Impact of combined modality treatment with radiotherapy and S-1 on T2N0 laryngeal cancer: Possible improvement in survival through the prevention of second primary cancer and distant metastasis.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Combination | 2017 |
Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as | 2017 |
Complete response of metastatic gastric cancer to chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; | 2017 |
Gemcitabine plus S-1 for metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; China; Deoxyc | 2018 |
Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Combined Modality Therapy; Cytokine-Induced Kille | 2019 |
Apatinib and S-1 combination therapy for the treatment of advanced head and neck neoplasms: Three case reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Drug Combinations; Head an | 2019 |
Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Br | 2019 |
Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; C | 2020 |
Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2014 |
Chemotherapy and resection for gastric cancer with synchronous liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations | 2013 |
[Assessment of the vulnerable elders survey as a predictive test for elderly patients with advanced or metastatic gastric cancer treated with combined S-1 and docetaxel therapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Data Collection; Docetaxel; | 2013 |
[Preoperative chemotherapy for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations | 2013 |
Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; | 2014 |
Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Disease Progression; Drug Combinations; Fem | 2014 |
[Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer - an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 2014 |
Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colonic Neoplasms; Dasatinib; Drug Combinat | 2014 |
Effectiveness and safety of tegafur-gimeracil-oteracil potassium (TS-1) for metastatic breast cancer: a single-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 2014 |
Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combin | 2015 |
[Efficacy of neoadjuvant chemotherapy for pancreatic carcinoma planned resection].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deo | 2015 |
Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
Topics: Adult; Aged; Anthracyclines; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Combinations; Drug-Relat | 2015 |
Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relati | 2015 |
[Clinical Response of Metastatic Colon Cancer to Chemotherapy with S-1 and Oxaliplatin - A Case Report].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Disease Pro | 2016 |
[Adjuvant Systemic Chemotherapy with S-1/Oxaliplatin or mFOLFOX6 after Curative Resection of Distant Metastases in Patients with Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dru | 2016 |
S-1 combined with cisplatin chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; H | 2016 |
Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; F | 2017 |
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tu | 2017 |
[A case of recurrent breast carcinoma metastasis successfully treated with S-1 and zoledronic acid therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Diphospho | 2009 |
Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo | 2009 |
[Two cases of effective S-1 monotherapy for patients with metastatic adenocarcinoma of the lung after multiple previous chemotherapies].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combin | 2009 |
Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Comb | 2010 |
[Three cases of metastatic breast cancer effectively treated with S-1 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Comb | 2010 |
[A case of long-term survival after undergoing S-1 treatment and splenectomy for liver, lung and splenic metastases following curative distal gastrectomy for gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; | 2010 |
[A case of interstitial pneumonitis induced by S-1].
Topics: Aged, 80 and over; Breast Neoplasms; Drug Combinations; Female; Humans; Lung Diseases, Interstitial; | 2010 |
A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplat | 2010 |
Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Surv | 2010 |
S-1 is an active anticancer agent for advanced thymic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Disease Progression; Disease-Free Survival; Drug C | 2010 |
[A case of multi-drug resistant breast cancer with liver metastasis treated effectively by S-1 monotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Combinations; Dru | 2010 |
CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Cisplati | 2011 |
[Analysis of patients with advanced gastric cancer undergoing S-1/CDDP combined neoadjuvant chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; H | 2011 |
[Chemotherapy of a 2-week S-1 administration followed by 1-week rest for advanced and metastatic breast cancer].
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Disease Progression; Drug Combinations; Female; Humans; M | 2011 |
Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Dr | 2011 |
[Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations | 2011 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2011 |
[Docetaxel plus S-1 as a second-line chemotherapy for metastasis or recurrence of esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophagea | 2012 |
[A case of advanced gastric cancer successfully treated with docetaxel and S-1 combined therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinati | 2012 |
The relationship between antitumor effects and relative dose intensity of S-1 plus cisplatin treatment for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug | 2012 |
The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 2012 |
Adjuvant chemotherapy with an oral fluoropyrimidine, S-1, following reduced RADPLAT in advanced laryngeal cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
[A case of early gastric cancer with cervical lymph nodes recurrence 5 years after a curative resection].
Topics: Biopsy; Combined Modality Therapy; Disseminated Intravascular Coagulation; Drug Combinations; Fatal | 2012 |
Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disea | 2004 |
Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1.
Topics: Adult; Aged; Drug Combinations; Drug Therapy, Combination; Female; Fluorouracil; Gene Expression; Hu | 2006 |
A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Dru | 2006 |
[Second-or third-line chemotherapy with CPT-11+TS-1 for 5 cases of metastatic and recurrent colorectal cancer].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2007 |
[Clinical study of S-1 for advanced gastric cancer after reduction surgery].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administration S | 2007 |
Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Disease Progression; Disease-Free Survival; Drug Combi | 2007 |
[Long-term survival case of advanced gastric cancer with paraaortic lymph node metastasis and peritoneal metastasis from S-1/CDDP combination therapy after reductive operation].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Drug Combinations; Fe | 2008 |
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell | 1996 |
[A case in which TS-1, an orally-administered 5-FU chemotherapeutic agent, showed marked effectiveness against scirrhous type gastric cancer with multiple organ metastases].
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocol | 2002 |